Paper39957776
The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India.
Bhargava A. Lancet Reg Health Southeast Asia, 2024. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India. Papers, record 39957776. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39957776
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36875946 | Pyridoxine in isoniazid-induced psychosis. | Sudan J Paediatr | 2022 | https://conductscience.org/library/papers/36875946 | PubMed |
| 2 | 38276634 | Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study. | Trop Med Infect Dis | 2023 | https://conductscience.org/library/papers/38276634 | PubMed |
| 3 | 30954757 | Prevalence of vitamin deficiencies in an apparently healthy urban adult population: Assessed by subclinical status and dietary intakes. | Nutrition | 2019 | https://conductscience.org/library/papers/30954757 | PubMed |
| 4 | 32462048 | Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame? | Open Forum Infect Dis | 2020 | https://conductscience.org/library/papers/32462048 | PubMed |
| 5 | 35849800 | How Flu-like Syndromes Contribute to Termination of Weekly Rifapentine-Based TB Preventive Therapy Is Still Poorly Predictable. | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/35849800 | PubMed |
| 6 | 28574024 | N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis. | Indian J Med Res | 2017 | https://conductscience.org/library/papers/28574024 | PubMed |
| 7 | 31605920 | Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. | Respir Med | 2019 | https://conductscience.org/library/papers/31605920 | PubMed |
| 8 | 29946528 | Pyridoxine for patients suffering from drug-susceptible tuberculosis in India. | Public Health Action | 2018 | https://conductscience.org/library/papers/29946528 | PubMed |
| 9 | 3775870 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. | Tubercle | 1986 | https://conductscience.org/library/papers/3775870 | PubMed |
| 10 | 2152443 | Reversal of prolonged isoniazid-induced coma by pyridoxine. | Arch Intern Med | 1990 | https://conductscience.org/library/papers/2152443 | PubMed |
| 11 | 22150035 | Three months of rifapentine and isoniazid for latent tuberculosis infection. | N Engl J Med | 2011 | https://conductscience.org/library/papers/22150035 | PubMed |
| 12 | 25904367 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25904367 | PubMed |
| 13 | 19351215 | Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. | Mol Diagn Ther | 2009 | https://conductscience.org/library/papers/19351215 | PubMed |
| 14 | 30361241 | Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. | Eur Respir J | 2018 | https://conductscience.org/library/papers/30361241 | PubMed |
| 15 | 33215187 | Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33215187 | PubMed |
| 16 | 2781610 | Severe 'flu'-like symptoms due to isoniazid--a report of three cases. | Tubercle | 1989 | https://conductscience.org/library/papers/2781610 | PubMed |
| 17 | 29910114 | Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. | Am J Prev Med | 2018 | https://conductscience.org/library/papers/29910114 | PubMed |
| 18 | 37567200 | Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. | Lancet | 2023 | https://conductscience.org/library/papers/37567200 | PubMed |
| 19 | 25337749 | High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25337749 | PubMed |
| 20 | 6614636 | Undesirable side effects of isoniazid and rifampin in largely twice-weekly short-course chemotherapy for tuberculosis. | Am Rev Respir Dis | 1983 | https://conductscience.org/library/papers/6614636 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42247627 | A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB‑YOUTH Study): Protocol for a Cluster Randomized Controlled Trial. | JMIR Res Protoc | 2026 | https://conductscience.org/library/papers/42247627 | PubMed |
| 42237122 | Clinical effectiveness of three months once-weekly Isoniazid and Rifapentine regimen for treatment of Latent TB Infection: a systematic review and meta-analysis. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/42237122 | PubMed |
| 42154079 | Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects. | Arch Microbiol | 2026 | https://conductscience.org/library/papers/42154079 | PubMed |
| 42020107 | Programmatic impact and cost-effectiveness of scaling up the short-course 3HP regimen for tuberculosis preventive treatment in Brazil. | BMJ Glob Health | 2026 | https://conductscience.org/library/papers/42020107 | PubMed |
| 41847763 | Implementation challenges of 3-month once-weekly rifapentine and isoniazid TB-preventive treatment in India. | Int Health | 2026 | https://conductscience.org/library/papers/41847763 | PubMed |
| 41732188 | Reappraising TB preventive treatment in India: programmatic and ethical implications of subclinical tuberculosis in household contacts. | Lancet Reg Health Southeast Asia | 2026 | https://conductscience.org/library/papers/41732188 | PubMed |
| 40326358 | Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). | Emerg Microbes Infect | 2025 | https://conductscience.org/library/papers/40326358 | PubMed |
| 40205610 | Advancement in diagnostic approaches for latent tuberculosis: distinguishing recent from remote infections. | One Health Outlook | 2025 | https://conductscience.org/library/papers/40205610 | PubMed |
| 40155893 | Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/40155893 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39957776
GET https://conductscience.org/api/papers/v1/39957776/references?page=2